Optimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK...

Area of Science:

• Cardiology
• Intensive Care Medicine
• Pharmacological Therapy

Background:

• Limited data exists on the long-term effects of pharmacological treatments for cardiogenic shock (CS) survivors.
• Investigating the impact of guideline-directed heart failure (HF) medical therapy (GDMT) on one-year survival is crucial for this patient population.

Purpose of the Study:

• To determine the association between GDMT and one-year survival rates in patients who have experienced CS.
• To evaluate the impact of comprehensive HF medical therapy on mortality outcomes following CS.

Main Methods:

• Analysis of the prospective, multicenter FRENSHOCK registry (n=535) including patients post-CS.
• Comparison of one-year mortality rates between patients receiving triple GDMT (beta-blockers, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists) and those not.
• Utilized propensity score matching and inverse probability treatment weighting to adjust for confounding factors.

Main Results:

• Triple GDMT was associated with significantly lower one-year all-cause mortality (adjusted hazard ratio 0.44 [95% CI, 0.19-0.80]; P=0.007).
• A stepwise decrease in mortality was observed as the number of HF drugs increased (log rank; P<0.001).
• Patients on triple GDMT had lower left ventricular ejection fraction on admission and discharge, indicating treatment in sicker patients.

Conclusions:

• Triple GDMT significantly reduces one-year mortality in survivors of cardiogenic shock.
• Intensified heart failure therapy should be strongly considered for patients recovering from CS.